Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles

MHC-I deficiency

Macrophage

CD47

Immunotherapy

Triple-negative breast cancer

Phagocytosis

Immune checkpoint

Innate immunity

© 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

Comments (0)

No login
gif